These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 21103788)
21. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. Yang ZJ; Zhao BB; Li L J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537 [TBL] [Abstract][Full Text] [Related]
22. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer. Wang B; Yu L; Yang GZ; Luo X; Huang L Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397 [TBL] [Abstract][Full Text] [Related]
23. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Shen Y; Li L Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144 [TBL] [Abstract][Full Text] [Related]
24. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer. Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787 [TBL] [Abstract][Full Text] [Related]
26. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer. Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000 [TBL] [Abstract][Full Text] [Related]
27. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer. Lv XL; Zhu Y; Liu JW; Ai H Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260 [TBL] [Abstract][Full Text] [Related]
28. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
29. Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. Biskup K; Braicu EI; Sehouli J; Fotopoulou C; Tauber R; Berger M; Blanchard V J Proteome Res; 2013 Sep; 12(9):4056-63. PubMed ID: 23889230 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718 [TBL] [Abstract][Full Text] [Related]
31. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors. Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814 [TBL] [Abstract][Full Text] [Related]
32. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941 [TBL] [Abstract][Full Text] [Related]
33. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178 [TBL] [Abstract][Full Text] [Related]
35. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China. Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075 [TBL] [Abstract][Full Text] [Related]
36. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339 [TBL] [Abstract][Full Text] [Related]
37. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231 [TBL] [Abstract][Full Text] [Related]
38. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052 [TBL] [Abstract][Full Text] [Related]
39. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression. Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060 [TBL] [Abstract][Full Text] [Related]
40. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]